Monday, November 12, 2018
Home Industry News THC Therapeutics Announces The US Patent office is granting a patent for...

THC Therapeutics Announces The US Patent office is granting a patent for their Cannabis Dryer

2
0

The dHydronator® is a Sanitizing Cannabis/Herb Sanitizing Dryer
LAS VEGAS, Nov. 08, 2018 (GLOBE NEWSWIRE) — THC Therapeutics Inc  (OTC: MBLC) is a forward-thinking publicly traded Health and Wellness company in the cannabis industry that has “Better Health through the Science of Nature” as their guiding statement. Today announced that they will focus their operations on the Cannabis industry and their soon-to-be issued patent for “The dHydronator®.”THC Therapeutics developed a sanitizing herb dryer, The dHydronator®, with multiple design, function, and usages. The Company anticipates that the patent will be issued within the next two months. This innovative, laboratory-proven product is specifically designed for drying and sanitizing freshly harvested Cannabis, herbs, teas, etc. The dHydronator® can reduce moisture content of Cannabis to 10% in only 10-14 hours. Traditional Cannabis drying times take up to two weeks.Another one of the major aspects of The dHydronator® is that it has been proven to destroy harmful surface contaminants & pathogens. With our built-in, SanitiZen® technology, we are able to reduce the microbial load from failing in cannabis and bring the contaminants down to passing levels.The dHydronator® has been tested by two independent laboratories  the last being DigiPath https://digipath.com/ (OTCQB: DIGP), testing covered over 6 strains and 9 independent tests to confirm the findings. The strains tested were Lucy Diamond, Cotton Candy, Blue Dream, Kings Cut, Pot of Gold and Diablo. Our SanitiZen technology brought the failing TAC (total aerobic count) from over 300,000 down to 78,000. The optimal drying time was determined to be 10-14 hours, but may vary by region and ambient humidity. By far the most surprising data from the testing was the potency of the cannabis after exposure to the dHydronator. Over the 9 tests and 6 strains, there was a 4% average increase of THC-A*.*See complete results at https://THCtherapeutics.com/index.php/dhydronator/These results exceeded our expectations and were surprising even to us. We cannot be be more pleased with what the dHydronator® can do.
In late July of 2018, the Company’s patent attorney received notice from the United States Patent and Trademark Office (the “USPTO”) that the USPTO would be allowing all 20 of our patent claims for The dHydronator®. In light of this development, and after analyzing the current regulatory environment regarding companies focused on investing in cryptographic tokens and other digital assets, the Company then determined that it would refocus its efforts on developing the soon-to-be patented dHydronator®, and the Company changed its name to “THC Therapeutics, Inc.”The Company also filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission on October 22, 2018. The Company intends to be a fully reporting issuer on December 21, 2018, which is 60 days from the date of the Form 10 filing. See- https://www.sec.gov/Archives/edgar/data/1404935/000147793218004955/mblc_1012ga.htmIn light of the Company’s name change and new business focus, the Company will be filing a notification with FINRA for a ticker symbol and name changeBrandon Romanek, our Founder and CEO, stated, “I could not be more elated that the US patent office has accepted ALL 20 of our claims for The dHydronator®. We filed for patent protection well over 2 years ago, but we did not expect to receive such broad protection on our intellectual property. Many experts in the cannabis industry liked our technology; however, they expressed serious doubts that we would receive any type of patent protection— much less the broad protection afforded by all 20 of our claims.”Romanek further commented, “Today THC Therapeutics is a much stronger company than we were just 8 months ago. Then, we only had a pending patent, with few other assets. Since then we have invested in Blockchain-related companies. We issued restricted shares to those companies and have the right to receive equity and/or tokens from those companies. https://www.impactppa.com and https://www.robotcache.com/ intend to have a token creation event by the first quarter of next year, and the Company expects to receive tokens in connection with them. I am a firm believer in Blockchain and Crypto, and plan to stay on top of regulatory and market changes.  I am pleased with the progress we have made since we went public in January of 2017 via reverse merger. We have taken solid steps to turn our vision into reality.”The Company intends to provide information regarding further updates on the patent status and its plans moving forward in future press releases.About THC TherapeuticsTHC Therapeutics, Inc. (OTC: MBLC) is focused on developing The dHydronator®, a sanitizing herb dryer. The main function of The dHydronator® is to greatly accelerate the drying time of a herb while sanitizing it. The dHydronator® can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis, and it will reduce the drying time for cannabis from 10-14 days to less than 14 hours. The Company plans to also focus some of its operations on participation in cannabis testing lab facilities and developing personal wellness centers, as well as investigating other potentially disruptive technologies The Company is seeking partnerships, mergers and acquisitions in the Cannabis, Health and Wellness industries in the United States & Canada. For more information, visit THCtherapeutics.com.Follow Brandon Romanek on Twitter:
Twitter @BrandonRomanek
Follow THC Therapeutics on Facebook
https://www.facebook.com/THCtherapetuics
About Digipath, Inc.Digipath, Inc. supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization.Forward-Looking Statements DisclosureThis press release may contain “forward-looking statements” within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company’s expected future business and financial performance, and often contain words such as “anticipates,” “beliefs,” “estimates,” “expects,” “intends,” ” plans,” “seeks,” “will,” and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.PR & Media Contact:
(702) 602-8422
info@THCtherapeutics.com

Original story can be found at: http://globenewswire.com/news-release/2018/11/08/1647863/0/en/THC-Therapeutics-Announces-The-US-Patent-office-is-granting-a-patent-for-their-Cannabis-Dryer.html?f=22&fvtc=5&fvtv=41223728